Cargando…
Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
No studies have compared mirtazapine with duloxetine in patients with major depressive disorder (MDD). Fifty-six patients were nonrandomly assigned to a 4-week treatment with either 15 to 45 mg/day of mirtazapine (n = 22) or 20 to 60 mg/day of duloxetine (n = 34). The primary efficacy measurements w...
Autores principales: | Nagao, Kei, Kishi, Taro, Moriwaki, Masatsugu, Fujita, Kiyoshi, Hirano, Shigeki, Yamanouchi, Yoshio, Funahashi, Toshihiko, Iwata, Nakao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678901/ https://www.ncbi.nlm.nih.gov/pubmed/23766648 http://dx.doi.org/10.2147/NDT.S43600 |
Ejemplares similares
-
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi, Taro, et al.
Publicado: (2017) -
A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi, Taro, et al.
Publicado: (2016) -
Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018) -
Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi, Taro, et al.
Publicado: (2014) -
Mirtazapine for Refractory Gastroparesis
por: Marella, Hemnishil K., et al.
Publicado: (2019)